NBIX : Summary for Neurocrine Biosciences, Inc. - Yahoo Finance

U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
53.62+1.84 (+3.55%)
At close: 4:00PM EDT

51.75 -1.87 (-3.49%)
After hours: 5:59PM EDT

People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close51.78
Bid51.52 x 500
Ask53.75 x 100
Day's Range51.95 - 53.85
52 Week Range37.35 - 55.15
Avg. Volume1,247,406
Market Cap4.67B
PE Ratio (TTM)-32.90
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire3 hours ago

    Neurocrine Announces Proposed Convertible Senior Notes Offering

    SAN DIEGO, April 25, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced its intention to offer, subject to market and other conditions, $450.0 million aggregate principal amount of convertible senior notes due 2024 (the "notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). The notes will be senior unsecured obligations of Neurocrine and will accrue interest payable semiannually in arrears. The notes will be convertible in certain circumstances into cash, shares of Neurocrine's common stock, or a combination of cash and shares of Neurocrine's common stock, at Neurocrine's election.

  • Benzinga5 hours ago

    Mark Your Calendar For These Days In May To Play The Volatility Around FDA Decision Dates

    Investment in biotech stocks is fraught with risks. These stocks trade in anticipation of some "make-or-break" events called catalysts and therefore face the danger of seeing wild swings in the ...

  • PR Newswire5 days ago

    Neurocrine Announces INGREZZA™ Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting

    SAN DIEGO, April 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) announced today that long-term safety and efficacy data from the KINECT 3 Phase III extension study of INGREZZA™ (valbenazine) capsules for the treatment of adults with tardive dyskinesia will be presented as a platform presentation at the American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 in Boston. Additionally, two posters representing additional data from several clinical trials of INGREZZA will be presented, including an analysis of its pharmacologic characteristics. "We are very pleased to present additional robust data from the largest ever clinical program in tardive dyskinesia at this year's American Academy of Neurology Annual Meeting," said Chris O'Brien, M.D., FAAN, Chief Medical Officer at Neurocrine.